



Complete Summary

GUIDELINE TITLE

Anticoagulation therapy supplement.

BIBLIOGRAPHIC SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Anticoagulant therapy supplement. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2003 Nov. 54 p. [107 references]

COMPLETE SUMMARY CONTENT

SCOPE

METHODOLOGY - including Rating Scheme and Cost Analysis

RECOMMENDATIONS

EVIDENCE SUPPORTING THE RECOMMENDATIONS

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

CONTRAINDICATIONS

QUALIFYING STATEMENTS

IMPLEMENTATION OF THE GUIDELINE

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT

CATEGORIES

IDENTIFYING INFORMATION AND AVAILABILITY

SCOPE

DISEASE/CONDITION(S)

- Conditions that require anticoagulation therapy (e.g., thrombosis)
- Conditions that may result from anticoagulation therapy (e.g., bleeding)

GUIDELINE CATEGORY

Management

Prevention

Risk Assessment

CLINICAL SPECIALTY

Cardiology

Emergency Medicine

Family Practice

Hematology

Internal Medicine

Neurology

INTENDED USERS

Advanced Practice Nurses
Allied Health Personnel
Health Care Providers
Health Plans
Hospitals
Managed Care Organizations
Nurses
Physician Assistants
Physicians

GUIDELINE OBJECTIVE(S)

- To provide a resource for the clinician in the use of anticoagulant drugs
- To help physicians make risk-benefit treatment decisions
- To serve as a tool to use for patients treated with anticoagulants
- To bring about consistency in recommendations that are common to the scope of related Institute for Clinical Systems Improvement (ICSI) cardiovascular guidelines: [Atrial Fibrillation](#); [Heart Failure in Adults](#); [Diagnosis and Initial Treatment of Ischemic Stroke](#); [Treatment of Acute Myocardial Infarction](#); [Venous Thromboembolism](#).

TARGET POPULATION

Any patient receiving antithrombotic therapy

Note: Refer to related National Guideline Clearinghouse (NGC) summaries of the Institute for Clinical Systems Improvement (ICSI) cardiovascular guidelines for specific target populations: [Atrial Fibrillation](#); [Heart Failure in Adults](#); [Diagnosis and Initial Treatment of Ischemic Stroke](#); [Treatment of Acute Myocardial Infarction](#); [Venous Thromboembolism](#).

INTERVENTIONS AND PRACTICES CONSIDERED

1. Anticoagulants
 - Warfarin (Coumadin®)
 - Unfractionated standard heparin (UFH)
 - Low-molecular-weight heparin (LMWH), such as enoxaparin (Lovenox®), dalteparin (Fragmin®), or tinzaparin (Innohep®)
 - Synthetic pentasaccharide, such as fondaparinux
 - Alternative agents, in selected cases: such as direct thrombin inhibitors lepirudin (Refludan®), argatroban (Acova®), and bivalirudin (Angiomax®)
2. Reversal of anticoagulation
 - Vitamin K
 - Fresh frozen plasma (FFP)
 - Protamine sulfate
3. Patient education
4. Monitoring of anticoagulation therapy by establishing target international normalized ratios (INRs) or by using activated partial thromboplastin times (aPTTs) or heparin assays or by performing periodic platelet counts

5. Bridging therapy (e.g., taking a patient off warfarin in the perioperative setting and "bridge" with heparin)

MAJOR OUTCOMES CONSIDERED

Safety and Efficacy of Anticoagulation

- Risk and incidence of adverse effects of anticoagulation, (e.g., major bleeding, skin necrosis, heparin induced thrombocytopenia)
- Therapeutic anticoagulation levels (e.g., international normalized ratio [INR])

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

Not stated

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Not stated

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Clinical Validation-Pilot Testing
Internal Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Institute Partners: System-Wide Review

The guideline annotation, discussion, and measurement specification documents undergo thorough review. Written comments are solicited from clinical, measurement, and management experts from within the member groups during an eight-week review period.

Each of the Institute's participating member groups determines its own process for distributing the guideline and obtaining feedback. Clinicians are asked to suggest modifications based on their understanding of the clinical literature coupled with their clinical expertise. Representatives from all departments involved in implementation and measurement review the guideline to determine its operational impact. Measurement specifications for selected measures are developed by the Institute for Clinical Systems Improvement (ICSI) in collaboration with participating member groups following implementation of the guideline. The specifications suggest approaches to operationalizing the measure.

Guideline Work Group

Following the completion of the review period, the guideline work group meets 1 to 2 times to review the input received. The original guideline is revised as necessary, and a written response is prepared to address each of the responses received from member groups. Two members of the Cardiovascular Steering Committee carefully review the input, the work group responses, and the revised draft of the guideline. They report to the entire committee their assessment of four questions: (1) Is there consensus among all ICSI member groups and hospitals on the content of the guideline document? (2) Has the drafting work group answered all criticisms reasonably from the member groups? (3) Within the knowledge of the appointed reviewer, is the evidence cited in the document current and not out-of-date? (4) Is the document sufficiently similar to the prior edition that a more thorough review (critical review) is not needed by the member group? The committee then either approves the guideline for release as submitted or negotiates changes with the work group representative present at the meeting.

Pilot Test

Member groups may introduce the guideline at pilot sites, providing training to the clinical staff and incorporating it into the organization's scheduling, computer, and other practice systems. Evaluation and assessment occur throughout the pilot test

phase, which usually lasts for three to six months. At the end of the pilot test phase, ICSI staff and the leader of the work group conduct an interview with the member groups participating in the pilot test phase to review their experience and gather comments, suggestions, and implementation tools.

The guideline work group meets to review the pilot sites' experiences and makes the necessary revisions to the guideline, and the Cardiovascular Steering Committee reviews the revised guideline and approves it for release.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

These recommendations supplement the recommendations on anticoagulation therapy provided in the National Guideline Clearinghouse (NGC) summaries of the Institute for Clinical Systems Improvement (ICSI) guidelines: [Atrial Fibrillation](#); [Heart Failure in Adults](#); [Diagnosis and Initial Treatment of Ischemic Stroke](#); [Treatment of Acute Myocardial Infarction](#); [Venous Thromboembolism](#).

Class of evidence (A-D, M, R, X) ratings are defined at the end of the "Major Recommendations" field.

Clinical Highlights

1. There are no circumstances under which patients absolutely should or should not receive anticoagulation therapy. Clinicians must consider the risks and benefits of anticoagulation therapy for a patient based upon the individual's risk for thrombosis if not treated weighed against their risk of bleeding if treated. (Introduction, Annotations #2, 3, 4, 9, 10, 11, 12)
2. In the initial phase of treatment for patients with active thrombosis (such as acute deep vein thrombosis [DVT]) or high risk of thrombosis, immediate-acting anticoagulant agents (unfractionated heparin [UFH]/low-molecular-weight heparin [LMWH]) should be used concomitantly with warfarin. (Annotation #5)
3. Loading doses and rapid induction of warfarin (Coumadin®) should be avoided. (Annotation #5)
4. Vitamin K may be used to reverse supratherapeutic anticoagulation with warfarin. The dose of vitamin K depends upon the degree of international normalized ratio (INR) elevation and/or signs and symptoms of bleeding (refer to Table 2 in the original guideline document). Vitamin K can lead to warfarin resistance and subsequently to an increased risk of thromboembolism. (Annotation #7)
5. Any prescription medication or over-the-counter remedy, including herbs, may alter the effectiveness of anticoagulants. (Annotations #5, 23, Annotations Appendices C, D, E - see original guideline document)
6. Regardless of the anticoagulant used, it is important that patients know they must always inform their physician and other health care providers that they are on anticoagulation therapy, especially if they are potentially undergoing an invasive procedure. (Annotations #6, 17; see also Appendix E in the original guideline document)

7. Patients should be encouraged and empowered to play an active role in the self-management of their treatment. Self-management is best initiated and sustained through active involvement of patients and family members with their multidisciplinary health care team. This educational partnership should be encouraged to decrease potential risks and improve understanding of the importance of patient adherence to their treatment regimen. (Annotation #6, 17; see also Appendix E in the original guideline document)

Warfarin

1. Introduction

Warfarin is used in the chronic management of patients with several types of thrombotic diseases. It produces its anticoagulant effect by inhibiting the vitamin K dependent production of clotting factors II, VII, IX, X, and proteins C and S. Warfarin is not fully effective in the initial several days of therapy because of a delayed reduction in some of the clotting factors that it inhibits. In the initial phase of treatment for patients with active thrombosis (such as acute deep vein thrombosis [DVT]) or high risk of thrombosis, immediate acting anticoagulant agents should be used concomitantly with warfarin.

2. Indications

Indications for use of warfarin are outlined in the Institute for Clinical Systems Improvement (ICSI) cardiovascular guidelines related to this supplement.

3. Contraindications

All contraindications are relative to a patient's risk for thrombosis weighed against their risk for bleeding while on anticoagulation therapy.

A. Warfarin Allergy or Intolerance

Acute rash, hepatitis, diarrhea, or nausea may indicate an allergy or intolerance to warfarin.

B. Hemorrhage

Anticoagulation with warfarin is contraindicated in patients with active hemorrhage with possible exceptions in certain circumstances such as disseminated intravascular coagulation as a result of malignancy. The decision to initiate anticoagulation should be individualized for patients with a history of recent hemorrhage. Again, this is dependent on circumstances including the type of hemorrhage and the indication for anticoagulation. Withholding anticoagulation for 4 to 6 weeks may be prudent for non-central nervous system bleeds. This duration may be longer for central nervous system (CNS) bleeds and needs to be assessed on a case-by case basis.

C. Pregnancy

Warfarin is contraindicated during pregnancy because it crosses the placenta causing teratogenicity and fetal bleeding. Unfractionated and low molecular weight heparins do not cross the placenta and do not cause teratogenicity or fetal bleeding. Therefore, unfractionated heparin (UFH) or a low-molecular-weight heparin (LMWH) should be used in place of warfarin. A recent study has shown that two pregnant patients with mechanical heart valves had thrombotic complications when treated with LMWH. Patients with mechanical heart valves and who are pregnant are at high risk and should be managed by an anticoagulation expert.

The amount of warfarin in breast milk is too small to affect the baby. As a result, breastfeeding is safe for mothers taking warfarin and for their infants.

Evidence supporting this recommendation is of class: R

D. Exclusion Criteria

Table 1: Exclusion Criteria Used in Trials Evaluating the Efficacy and Tolerability of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation

Note: The potential increased risk of bleeding must be balanced against the potential decreased risk of thromboembolism.

Active bleeding Active peptic ulcer disease Known coagulation defects Thrombocytopenia (platelet $<50,000/\text{mm}^3$) or platelet dysfunction Recent hemorrhagic stroke Noncompliant or unreliable patients Patient is psychologically or socially unsuitable Dementia or severe cognitive impairment History of falls (3 within the previous year or recurrent, injurious falls) Excessive alcohol intake Uncontrolled hypertension ($>180/100$ mm Hg) Daily use of nonsteroidal anti-inflammatory drugs (NSAIDs) Planned invasive procedure or major surgery
--

From: Sebastian J, and Tresch D. "Use of oral anticoagulants in older patients." *Drugs & Aging* 16:409-35, 2000. (Class R)

See Annotation Appendix A and the Discussion Section in the original guideline document for additional information about predicting the risk of bleeding for individual patients.

4. Adverse Effects A. Bleeding

The most common adverse effect of warfarin is bleeding. Risk factors for bleeding should not be considered absolute contraindications to anticoagulant therapy. Some risk factors for bleeding (such as age) are also risk factors for thromboembolism. The potential increased risk of bleeding must be balanced against the potential decreased risk of thromboembolism. Risk of bleeding is reduced by using lower intensity of anticoagulation and by avoiding concomitant use of aspirin. See Annotation Appendix A and the Discussion Section in the original guideline document for additional information on bleeding risk in anticoagulation therapy.

B. Skin Necrosis

Skin necrosis is a rare but serious complication of warfarin therapy that typically occurs on the third to eighth day of therapy. Warfarin should be discontinued in patients with evidence of skin necrosis. These patients should be placed on heparin unless there is evidence of heparin induced thrombocytopenia (HIT).

C. Purple Toe Syndrome

Purple toe syndrome and other manifestations of peripheral emboli may rarely complicate warfarin therapy, usually 3 to 10 weeks after initiation of therapy. Causes of purple toe syndrome other than warfarin should be considered when making a treatment decision. These include vasculitis, acute myocardial infarction (MI) with embolism, and diabetes mellitus.

D. Less Serious Adverse Effects

Adverse effects that are less serious include alopecia, osteoporosis, gastrointestinal discomfort, and rash. Management of these adverse effects should be managed on an individual basis.

5. Evidence supporting this recommendation is of classes: B, D, R

5. Dosing

A. General Principles of Warfarin Dosing

1. Loading doses and rapid induction of warfarin should be avoided. Warfarin (irrespective of international normalized ratio [INR]) is not fully effective in the first several days of therapy because of a delayed decrease in several circulating clotting factors. Loading doses can increase a patient's risk of supratherapeutic INR and make it more difficult to determine a steady-state dose.
2. Patients at high risk of thrombosis, such as those with an active thrombotic process (e.g., venous thromboembolism) or an underlying malignancy, should be treated with concomitant heparin and warfarin therapy. Patients at lower thrombotic risk (e.g., atrial fibrillation without recurrent thromboembolism) can be initiated on warfarin alone.

3. A single target INR value should be used as a goal endpoint. This will decrease the odds of a patient being above or below desirable range of INR. The target INR for most conditions is 2.5 with an acceptable range of 2.0 to 3.0. Other thrombotic conditions (e.g., mitral mechanical valves) have recommended targets of 3.0 (range 2.5 to 3.5). A table of recommended therapeutic ranges for oral anticoagulant therapy is attached in Annotation Appendix B of the original guideline document. Also, individual disease management guidelines such as [Atrial Fibrillation](#) and [Venous Thromboembolism](#) give specific INR recommendations.
4. The risk of bleeding for patients on warfarin increases substantially at INR values greater than 4.0. This risk is magnified if one or more risk factors are present. Consider hemorrhagic risk in all dosing decisions. See Annotation Appendix A of the original guideline document for more information on risk factors for bleeding during warfarin therapy.
5. There is a significant increase in thromboembolism as INR values decrease below INR 1.7. Clinical risk and past medical history should be considered in all dosing decisions. Higher risk may require more aggressive dosing.
6. In most cases, holding warfarin for 4 days prior to surgery results in an INR value of 1.2 or less. Expect advanced age and drug interactions to result in a slower decline. Patients with high risk of thromboembolism may need coverage with heparin for a portion of this time. For more information, see Annotation #20, "Bridging Therapy."
7. Some equivalency studies have shown that substitution of generic warfarin for brand name Coumadin® may provide equivalent anticoagulation response if the manufacturer of the generic warfarin has followed the standards set for the name brand. Care must be taken to remain with either the brand name product or the same generic product. Do not switch from brand to generic or between generics.
8. Prescription and over-the-counter medications can adversely affect the INR response to warfarin. Herbal or natural remedies can change the INR response to warfarin and/or increase a patient's risk of bleeding. In these instances, additional monitoring may be needed. See Annotation Appendices C and D in the original guideline for more information on drug interactions with warfarin.
9. Foods that contain moderate amounts of vitamin K may decrease the INR response to warfarin. See Annotation Appendix E in the original guideline document for a guide to educating patients regarding warfarin therapy.
10. Direct thrombin inhibitors (hirudin, argatroban, bivalirudin) and heparins can affect the INR. See Annotation Appendix G in the original guideline document for more information on direct thrombin inhibitors.

Evidence supporting this recommendation is of classes: A, B, D, R

B. Initiation of Warfarin

1. Average Daily Dosing Technique (for patients not on heparin)
 - a. Patients receiving warfarin for the first time should begin at an average dose of 5 mg daily with a recheck of INR in 2 to 3 doses. Moderate initiation doses should be considered for patients with any of the following factors: age greater than 75 years, multiple comorbid conditions, poor nutrition (low albumin), elevated INR when off warfarin, elevated liver function tests, or changing thyroid status. Average daily dosing technique is useful for patients off UFH and LMWH. Higher initial dosing nomograms have not shown consistent benefit.
 - b. Therapy for patients previously taking warfarin can be initiated at the previous dose.
 - c. A baseline INR value may be drawn to rule out underlying coagulopathy.
 - d. If the INR is 2.0 or greater after the first 3 doses, consider decreasing the dose by one-half. Always search for causes of rapid rise in INR.
 - e. Subsequent INR values are determined at 2 to 3 times weekly for 1 to 2 weeks, then less often depending on the stability of the INR result.
 - f. Steady state anticoagulation occurs between 6 to 12 days. Expect obese patients and patients of advanced age to have a slower time to steady state.

Evidence supporting this recommendation is of class: A

2. Flexible Daily Dosing Technique (for patients on heparin)
 - a. Patients are given daily doses of warfarin, adjusted according to the daily INR, until a weekly dose can be determined. The flexible daily dosing technique is useful for patients on concomitant UFH or a LMWH.
 - b. The dose-response relationship is best interpreted when there are at least 16 hours between dose and laboratory draw.
 - c. For patients who weigh more than 80 kg, a higher estimated average initial dose of 7.5 mg may be given.

Evidence supporting this recommendation is of class: D

C. Maintenance Dosing of Warfarin

Numerous factors should be considered with regard to warfarin dosing, including diagnosis, sensitivity to warfarin, age (especially if elderly), patient compliance, other medications (e.g., amiodarone), body mass, alcohol consumption, nutritional status, diet/dietary changes, activity level, race, and accuracy of laboratory results.

1. Dose adjustments should be made in increments of up to 15% of the weekly dose.

2. An assessment of clinical variables known to affect the INR should be made with each dose adjustment. Always search for the cause of out-of-range values and address them before adjusting the dose.
3. Expect a 15% dose adjustment to result in an approximately 1.0 INR change. Likewise, a 10% dose adjustment will result in an approximate 0.7 to 0.8 INR change.
4. Steady-state INR values will not be realized for up to 3 weeks following a dose adjustment.
5. Patients with INR values ± 0.5 INR out-of-range should be considered for more frequent monitoring and should have a repeat INR within seven days.
6. If two consecutive weekly INR values are within range and there has not been a change in warfarin variables, increase the interval between draws to 2 weeks.

6. Monitoring

A. Principles of Monitoring Warfarin Therapy

1. The dose-response relationship is best interpreted when at least 16 hours elapse between dose and lab draw.
2. Plasma for INR testing should be anticoagulated using 3.2% citrate.
3. INR determinations should be obtained monthly in most stable patients, but not more than 6 weeks should elapse between determinations.
4. Heparin and lupus anticoagulants may spuriously prolong INR results obtained by some instrument-reagent combinations.

Evidence supporting this recommendation is of classes: B, D, R

B. Options for Monitoring and Management

1. Over the past decade, options for monitoring and managing warfarin have emerged. With the improvement of point-of-care instruments, the INR can now be measured in the office (office point-of-care monitoring) or at home by the patient (self-monitoring) as well as in the laboratory.
 - a. Point-of-care coagulation instruments using whole blood or plasma specimens can be utilized for INR testing. Accuracy and precision data should be evaluated when selecting one of these instruments.
 - b. INRs obtained simultaneously on the same blood sample using point-of care and laboratory instruments will not be identical due to differences in reagents, testing methods, and specimen type.
 - c. Accuracy of a point-of-care instrument can diminish over time due to changes in reagents, aging of the detection system, and poor maintenance. Periodic accuracy checks with the laboratory coagulation analyzer are indicated.
 - d. Each point-of-care instrument should be evaluated to determine the range of accurate INR results (reportable

range). INR results outside this range should be confirmed in the laboratory.

2. Traditionally, warfarin has been monitored and managed by the patient's personal physician. However, much like diabetes, new management options have emerged including anticoagulation clinics staffed by pharmacists and/or registered nurses, and patient-directed management (self-management). These anticoagulation programs have been shown to significantly reduce patients' risks of adverse outcomes.

See Discussion #6, B2 in the original guideline document for resources on development and support of anticoagulation clinics.

- C. Evidence supporting this recommendation is of classes: B, C, D, R

C. Key Patient Education Components: Warfarin

1. Mechanism of action of warfarin: it depletes certain coagulation factor proteins in the blood.
2. Time of day to take warfarin: it should be taken at approximately the same time and is taken in the evening. Due to the short half-life of factor VII and its influence on the INR, this is especially important if the patient will have an INR drawn the next morning.
3. Explanation of INR, target range and regular testing
4. Signs and symptoms of bleeding and that the provider should be contacted immediately if bleeding signs are present
5. Need to notify provider if illness, injury, or change in physical status occurs
6. Need to inform all their health care providers that they are on anticoagulation therapy, especially if they are potentially undergoing an invasive procedure, surgery or dental work
7. Drug interactions:
 - What to do if a new medication is initiated or a medication is discontinued, especially if the interaction with warfarin is unknown: check INR within 3 to 4 days.
 - Drugs that affect the absorption of warfarin
 - Drugs that increase or decrease the effect of warfarin
 - Common over-the-counter medication interactions, including aspirin, non-steroidal anti-inflammatory drugs (NSAID), acetaminophen, natural or herbal remedies, laxatives, antacids, and multivitamin preparations containing vitamin K
8. Role of vitamin K and the importance of consistency of vitamin K rich foods in the diet rather than avoidance of vitamin K rich foods
9. Importance of minimizing trauma risks associated with activities at high risk for injury
10. Effect of exercise: increased activity results in decreased effect of the drug
11. Effect of personal habits: e.g., alcohol, chewing tobacco

12. Effect of certain conditions: congestive heart failure, thyroid disease, gastroenteritis, and diarrhea
13. Importance of self-monitoring: maintain a log of INRs, dose of warfarin, etc.
14. Medic Alert bracelet/necklace and warfarin ID card

See the Annotation Appendix E in the original guideline for a guide to patient education regarding warfarin therapy.

7. Correction of Supratherapeutic Anticoagulation Caused by Warfarin

Supratherapeutic anticoagulation may occur with patients taking warfarin. Vitamin K may be used to reverse the effects of warfarin; however, vitamin K can lead to warfarin resistance and, subsequently, to an increased risk of thromboembolism.

Important Considerations for Vitamin K Dosing

1. In an outpatient clinic setting, oral vitamin K is the preferred route of administration.
2. In a hospital setting, when patients are nothing per mouth (NPO) or ill, intravenous vitamin K may be the preferred route of administration. To avoid anaphylactic reactions, vitamin K should be given over 30 minutes in a mixture of dextrose 5% in water (D5W) 50 mL under monitored conditions. It is not necessary to premedicate with corticosteroids or antihistamines.
3. Administration of subcutaneous vitamin K can lead to erratic correction of the INR and unpredictable resistance to warfarin.
4. Intramuscular injections of vitamin K should be avoided.

Refer to Table 2 in the original guideline document for details on correction of supratherapeutic warfarin anticoagulation caused by warfarin.

Evidence supporting this recommendation is of classes: A, B, C, D, R

Heparin (Unfractionated and Low-Molecular-Weight Heparins) and Synthetic Pentasaccharide (Fondaparinux)

8. Introduction

Heparin's (UFH, LMWH) anticoagulant effect is due to the presence of a pentasaccharide sequence which potentiates the action of antithrombin III leading to inactivation of several clotting factors, primarily factors Xa and IIa. Heparins have relatively rapid onset of action compared to warfarin and are often the first drug used in acute thrombotic situations.

UFH is derived from porcine or bovine sources. It has variable absorption, metabolism, and pharmacokinetic effects on anticoagulation. Monitoring is required in most patients treated with this drug.

LMWH are depolymerized byproducts of UFH. Pharmacological advantages of LMWH relate to superior absorption and consistent dose effect response.

Fondaparinux is a synthetic compound composed of the essential pentasaccharide sequence.

9. Indications

Indications for use of UFH, LMWH, and fondaparinux are outlined in the Institute for Clinical Systems Improvement (ICSI) guidelines related to this supplement.

10. Contraindications

- A. Active major bleeding including intracerebral hemorrhage within past two weeks, subarachnoid hemorrhage until definitively treated
- B. Hypersensitivity to heparin or pork products
- C. Heparin-induced thrombocytopenia (HIT)
- D. Thrombolytics given within past 24 hours for acute stroke
- E. Renal failure (LMWH and fondaparinux)
- F. Fondaparinux has a long elimination half-life and there is no antidote for reversal; therefore, patients who may require rapid reversal are not candidates for this therapy.

11. Precautions

- A. Active or history of recent gastrointestinal ulceration and hemorrhage
- B. Bacterial endocarditis
- C. Bleeding diathesis
- D. Concomitant therapy with agents that inhibit platelets
- E. Congenital or acquired bleeding disorders
- F. Hemorrhagic stroke
- G. Status post brain, spinal, or ophthalmologic surgery
- H. Uncontrolled arterial hypertension
- I. Diabetic retinopathy

12. Adverse Effects

A. Bleeding

Risk of bleeding increases with treatment related factors such as dose, duration, and use of thrombolytics and/or antiplatelet agents, and patient-related factors including age over 70 years, recent trauma or surgery, coagulopathy, peptic ulcer, neoplasm, or renal failure.

Evidence supporting this recommendation is of classes: A, R

B. Adverse Effects in Pregnancy

UFH and LMWH do not cross the placenta and therefore do not cause teratogenicity or fetal bleeding, though bleeding at the uteroplacental junction is possible. Heparin is not secreted in breast milk and can be given safely to nursing mothers.

Major bleeding occurs at similar rates in pregnant and non-pregnant women receiving heparin. LMWHs cause less heparin-induced thrombocytopenia and bone loss during pregnancy than UFH.

When possible, patients using UFH or a LMWH should have a planned delivery. UFH should be discontinued 6 hours prior to a planned delivery. LMWH should be discontinued 24 hours prior to a planned delivery.

The pharmacokinetics of LMWH in pregnancy are significantly altered. Consideration should be given to monitoring the antifactor Xa activity at 12 to 15 weeks and 30 to 33 weeks.

A recent study has shown that two pregnant patients with mechanical heart valves had thrombotic complications when treated with LMWH. Because of this, the Food and Drug Administration (FDA) and the manufacturer have warned that enoxaparin is not presently indicated for use in prophylaxis for heart valve patients who are pregnant. However, multiple registries of other heart valve patients have shown no such problems with therapeutic LMWH therapy. The workgroup feels that, although LMWH use is likely as safe as the alternative (bridging with UFH), patients should be made aware of this area of controversy before LMWH is used.

Patients with mechanical heart valves and who are pregnant are at high risk and should be managed by an anticoagulation expert.

There is limited data on use of fondaparinux in pregnancy. It is unknown if fondaparinux is excreted in human breast milk. Animal studies have been positive for excretion.

Evidence supporting this recommendation is of class: R

C. Heparin-Induced Thrombocytopenia (HIT)

HIT is an immune-mediated reaction to heparins. It occurs in 2 to 3% of patients treated with UFH and <1% of patients treated with LMWH. This syndrome can be associated with paradoxical increased risk for venous and arterial thrombosis. Patients who develop HIT without associated thrombosis will have a significant risk for thrombosis in the subsequent 100 days. Patients with a history of HIT should not be treated with UFH or LMWH.

Patients who develop a greater than 50% decrease in platelet count from baseline labs or absolute platelet count less than 100,000 mm³ while on heparin should have their heparin stopped while antibody testing for HIT is performed. Direct thrombin inhibitors (DTIs) are the alternative anticoagulant of choice for patients with HIT. Three brands are FDA approved: lepirudin (Refludan®), argatroban, and most recently bivalirudin (Angiomax®).

Although in vitro data has not demonstrated cross reactivity of fondaparinux with HIT antibodies, additional studies are needed before its use can be considered. Thrombocytopenia can occur in patients treated with fondaparinux.

See Annotation Appendix G in the original guideline document for more information on direct thrombin inhibitors.

Evidence supporting this recommendation is of classes: C, D, R

Unfractionated Heparin

13. Dosing

A. General Principles of Adult UFH Dosing

1. Weight-based, institution specific nomograms are strongly recommended for patients on therapeutic intravenous UFH. However, each institution must develop its own nomograms based upon their unique specific therapeutic ranges. See Annotation Appendix F in the original guideline document for an example of a heparin nomogram.
2. Before administering UFH, the patient's height in centimeters and weight in kilograms and any adverse reactions to drugs or food, including a description of the reaction, should be noted.
3. Before administering UFH, draw hemoglobin/hematocrit, platelet count, activated partial thromboplastin time (aPTT) and prothrombin time (PT) if not done at admission.

B. Initiation of UFH

1. An initial bolus dose of heparin is recommended followed by intravenous infusion, with the exception of acute stroke. The use of heparin in patients with acute stroke is controversial. See the NGC summary of the ICSI guideline [Diagnosis and Initial Treatment of Ischemic Stroke](#). Note the time of initial heparin bolus.
2. After initial intravenous bolus of heparin, begin maintenance drip per institutional protocols.

C. Maintenance

1. Obtain an aPTT level or heparin assay six hours after the initiation of intravenous heparin drip. Adjust the intravenous drip according to institutional protocols. (See Annotation Appendix F in the original guideline document).
2. A standard weight-based protocol for heparin administration should not be used for patients receiving parenteral platelet receptor glycoprotein IIb/IIIa antagonist (abciximab or ReoPro®), tirofiban (Aggrastat®), eptifibatide (Integrilin®), and/or thrombolytics (alteplase or Activase®). Treating physicians should refer to the specific recommended protocols for treating patients using the package insert for the individual thrombolytic or other agent, or refer to their institution's protocols.

Evidence supporting this recommendation is of classes: A, B

14. Monitoring

A. Principles of Monitoring UFH Therapy

1. UFH treatment of thrombosis can be monitored using an aPTT or heparin assay. The recommended test for monitoring UFH, including the therapeutic range for the test, should be provided by the laboratory. Of note, aPTT results vary among institutions due to differences in laboratory instruments and reagents.

Evidence supporting this recommendation is of classes: B,R

2. Patients receiving UFH or a LMWH should be monitored for heparin-induced thrombocytopenia (HIT) with a platelet count beginning at baseline, then every other day. A platelet count of less than $100,000 \text{ mm}^3$ or less than 50% of baseline may indicate the development of HIT. See Annotation 12C in the original guideline document for more information.

Note: Patient who have not received heparin within the previous 3 months are unlikely to develop HIT within the first 3 days of treatment; however, patients who have received heparin within 3 months may develop HIT more rapidly. Based on this information, the workgroup had previously recommended that patients who had received heparin within the past 3 months have their platelet count monitored beginning on day 3 and that the patients who had not received heparin within the past 3 months have their platelet monitored beginning on day 5. Unfortunately, patients are not always aware that they have received heparin (with surgery, central intravenous catheters, etc.) For the sake of safety and simplicity, the workgroup now recommends a platelet count every other day for all patients receiving UFT or LMWH.

15. Correction of Supratherapeutic Anticoagulation Caused by UFH

Serious bleeding is an indication for reversal of heparin therapy. To achieve reversal, protamine sulfate is administered by slow intravenous infusion over 10 minutes as follows:

Hourly UFH rate (units) x 1.75 = protamine dose (mg)

Hypotension is an adverse effect of protamine treatment. Anaphylaxis occurs in 1% of patients who have previously received protamine (such as NPH insulin).

Evidence supporting this recommendation is of class: R

Low Molecular Weight Heparin

16. Dosing

General Principles of Adult Dosing LMWH

1. Therapeutic doses of a LMWH are different from prophylactic doses.
2. Doses of different types of heparins are not interchangeable.
3. The anticoagulant effect of LMWH can extend beyond 24 hours after administration.
4. The dose should be modified for patients with impaired renal function. LMWH is relatively contraindicated in patients with a creatinine greater than or equal to 2.0 mg/dL or who are receiving dialysis.
5. The optimal dose of LMWH has not been established in patients with low body weight (less than 50 kg), obesity, renal insufficiency, or pregnancy. It may be necessary to monitor the anti-Xa level in these patients.

Evidence supporting this recommendation is of classes: A, D, R

Refer to Table 3 in the original guideline document for therapeutic dosing of LMWH and Table 4 for prophylactic dosing of LMWH.

17. Monitoring

A. Principles of Monitoring

1. In most clinical situations, monitoring of LMWH is not required.
2. Indications for monitoring of LMWH include renal insufficiency (calculated creatinine clearance <30), obesity, very low body weight, and pregnancy. To calculate the estimated creatinine clearance, use the Cockcroft-Gault equation as follows:

In men:

$$\text{Creatinine clearance} = \frac{(140 - \text{age}) \times \text{weight in kg}}{(72 \times \text{serum creatinine})}$$

In women:

$$\text{Creatinine clearance} = \frac{(140 - \text{age}) \times \text{weight in kg} \times 0.85}{(72 \times \text{serum creatinine})}$$

3. The suggested therapeutic range for twice daily dosing is 0.6 to 1.0 IU/mL obtained 4 hours after subcutaneous injection. One suggested target range for once daily dosing is 1.0 to 2.0 IU/mL obtained 4 hours after subcutaneous injection.

B. Monitoring of LMWH

1. The recommended test for monitoring LMWH is an antifactor Xa assay (heparin assay). An antifactor Xa assay standard curve must be constructed for each LMWH preparation used in the care system. Appropriate commercial controls can be used if available. Although the aPTT may be prolonged in patients on LMWH, it does not reliably reflect LMWH activity.

2. Pretreatment and periodic platelet counts should be performed to identify developing heparin induced thrombocytopenia (HIT) (see Annotation #14, "Monitoring").

C. Key Patient Education Components: LMWH

1. Over-the-counter and prescription drugs which should not be taken while on LMWH
2. Importance of understanding heparin assay, INRs and target ranges
3. Know and watch for signs of bleeding
4. Proper technique for injecting LMWH
5. Restrictions for other conditions including deep vein thrombosis, stroke, or coronary artery disease. Refer to related ICSI guidelines for more information.
6. Importance of adhering to prescribed regimen

Evidence supporting this recommendation is of class: R

18. Correction of Supratherapeutic Anticoagulation Caused by LMWH

No agent, including fresh frozen plasma (FFP) and vitamin K, is effective for complete reversal of supratherapeutic anticoagulation with LMWH. Reversal of LMWH with protamine sulfate may be incomplete, with neutralization of 60 to 75% at most. However, protamine should be considered in patients with severe life-threatening bleeding.

- The dose of protamine to reverse dalteparin is 1 mg protamine per 100 anti-Xa IU of dalteparin (Fragmin®). A second dose of protamine may be given at 100 ant-Xa IU of dalteparin if the aPTT measured at 2 to 4 hours after the first protamine infusion is prolonged.
- The dose of protamine needed to reverse enoxaparin is 1 mg protamine per 1 mg of enoxaparin (Lovenox®). A second dose of protamine may be given at 0.5 mg protamine per 1 mg enoxaparin if the aPTT measured at 2 to 4 hours after the first protamine infusion is prolonged.

Evidence supporting this recommendation is of class: D

19. Precautions

A. Spinal or Epidural Anesthesia or Spinal Puncture

Bleeding or hematomas within the spinal column may result when a heparin product or fondaparinux is used concurrently with spinal or epidural anesthesia or spinal puncture. The risk for complication increases with placement or removal of catheters in the spinal canal and by traumatic or repeated epidural or spinal puncture. Use of other drugs affecting the blood clotting mechanism, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants, also increases the risk of complication.

1. If a continuous epidural anesthesia is administered, the decision to implement LMWH prophylaxis in the presence of an indwelling catheter must be made with extreme care. If LMWH prophylaxis is administered while the patient is receiving continuous epidural anesthesia, the patient must be monitored carefully for early signs of cord compression (e.g., progression of lower extremity numbness or weakness, or bowel or bladder dysfunction).
2. If LMWH prophylaxis is administered while the patient is receiving continuous epidural anesthesia, removal of the catheter should be delayed 10 to 12 hours after the dose of LMWH.
3. LMWH prophylaxis should be delayed 2 hours after placement of the spinal needle or removal of the catheter.

Evidence supporting this recommendation is of classes: D, R

B. Regional Anesthesia

Regional anesthesia should be avoided in patients with a history of abnormal bleeding or if taking medications that affect hemostasis (e.g., aspirin, NSAIDs, platelet inhibitors, warfarin)

1. If a regional anesthetic is administered, a single-dose spinal anesthetic is preferable to continuous epidural anesthesia.
2. If a LMWH is administered preoperatively, insertion of the spinal needle should be delayed at least 8 to 12 hours after the dose of LMWH. Regional anesthesia should be avoided if there is a hemorrhagic aspirate during insertion of the spinal needle.

C. Other Precautions

1. LMWH should not be administered by intramuscular injection.
2. Carefully monitor patients for possible spinal or epidural bleeding. Treat immediately if neurological impairment is detected.

20. Bridging Therapy

- A. Patients on warfarin therapy for prevention of thromboembolism who need an invasive procedure may require parenteral anticoagulation perioperatively.
 1. The decision to take a patient off warfarin, and "bridge" with heparin is determined by the balance of bleeding risk due to the surgical procedure and clotting risk due to the underlying disorder.
 2. Patients who have procedures that are of low bleeding risk (e.g., skin biopsies and most dental procedures) can be continued on uninterrupted warfarin anticoagulation.
 3. An individual's history of thromboembolism will assist with the decision-making.
 - a. If a patient is at low thromboembolic risk (such as atrial fibrillation without prior cerebrovascular accident [CVA] or remote history of a venous thromboembolic event),

warfarin may be stopped 4 to 5 days prior to the procedure and resumed the evening of surgery.

- b. If a patient is at high thromboembolic risk (such as mechanical mitral valve with atrial fibrillation), bridging with therapeutic doses of LMWH may be indicated. Small cohort studies with dalteparin and enoxaparin have shown benefits in bridging.

A recent study has shown that two pregnant patients with mechanical heart valves had thrombotic complications when treated with LMWH. Because of this, the FDA and manufacturer have warned that enoxaparin is not presently indicated for use in prophylaxis for heart valve patients who are pregnant. However, multiple registries of other heart valve patients have shown no such problems with therapeutic LMWH therapy. The workgroup feels that, although LMWH use is likely as safe as the alternative (UFH), patients should be made aware of this area of controversy before LMWH is used.

Patients with mechanical heart valves and who are pregnant are at high risk and should be managed by an anticoagulation expert.

- c. In general, therapeutic doses of UFH or LMWH have been used to bridge a patient perioperatively. In some cases, prophylactic dosing of LMWH may be indicated. An example of prophylactic postoperative LMWH dosing may be if the patient has an increased risk for postoperative deep vein thrombosis.

- B. Due to the complexity of bridging therapy and the need for individualized treatment, consultation with a hematologist or expert in anticoagulation may be helpful.
- C. If a patient is to receive bridging therapy, the patient or a caregiver must show proficiency in the injection technique and proficiency with adhering to the perioperative schedule.
- D. The following schedule may be used if the decision to bridge has been made.

Table: Recommended Bridging Schedule

Please be aware that this schedule is not FDA-approved and there are no randomized controlled trials that have studied the efficacy of this schedule.

Days Before Procedure	Warfarin	INR	LMWH* or Therapeutic UFH
5 days prior to procedure	Last dose if target INR is 3.0	Check if not done within 2 weeks prior	4-5 days before procedure, start after first missed warfarin dose

Days Before Procedure	Warfarin	INR	LMWH* or Therapeutic UFH
4 days prior to procedure	Last dose if target INR is 2.5	Check if not done within 2 weeks prior	4-5 days before procedure, start after first missed warfarin dose
3 days prior to procedure	None	None	AM and PM dose
2 days prior to procedure	None	None	AM and PM dose
1 day prior to procedure	None	Check INR; 1-2.5 mg oral Vitamin K as needed if INR >1.5	AM dose only – at least 18 hours between dose and procedure
Procedure	Resume at regular dose	As indicated by surgeon	Start at least 12 hours post procedure – see Annotation #19 of guideline
1 day after procedure	Regular dose	Daily as needed – may be skipped	Restart if hemostasis achieved
2 days after procedure	Regular dose	Daily as needed	Restart if hemostasis achieved
3 days after procedure	Regular dose	Daily until INR >minimum acceptable x 1 day	Continue until INR >minimum acceptable x 2 day

*If enoxaparin (Lovenox®) is used as the LMWH, dosing is every 12h (a.m. and p.m.) Once a day dosing is used if the LMWH is tinzaparin (Innohep®) or dalteparin (Fragmin®).

- E. For dental procedures, a review of the literature has shown that in most cases, no change in warfarin is needed. It may be reasonable to allow the patient to "drift" to the lowest effective INR prior to a dental procedure. Local bleeding may be controlled with a variety of techniques including pressure, biting on tea bags, gelatin sponges, and topical thrombin. Other means of local hemostasis control include tranexamic acid mouthwash or epsilon aminocaproic acid packing.

Evidence supporting this recommendation is of classes: D, R

Synthetic Pentasaccharide (Fondaparinux)

21. Dosing

General Principles of Adult Dosing Fondaparinux

- A. Current FDA approved indication is limited to prophylaxis of venous thrombosis in patients undergoing surgery for hip fracture or hip or knee replacement.
- B. Therapeutic doses are different than prophylactic dosing.
- C. Fondaparinux is not recommended for patients with platelets less than 100,000 mm³ or for those weighing less than 50 kg.
- D. Dose should be modified in patients with renal impairment; however, it should not be used in dialysis-dependent patients.

See Table 6 in the original guideline document for information on FDA approval status, indications, and dosing of fondaparinux.

Evidence supporting this recommendation is of classes: A, M

22. Monitoring

The heparin assay (anti factor Xa) has been used to monitor effects of fondaparinux; however, in most clinical situations, monitoring may not be necessary.

Fondaparinux may cause transient elevations in serum aminotransferases. This effect is reversible and routine monitoring is not recommended.

Additional information on fondaparinux is included in the NGC summary of the ICSI guideline [Venous Thromboembolism \(VTE\) Prophylaxis for Surgical/Trauma Patients](#).

Definitions:

Classes of Research Reports:

A. Primary Reports of New Data Collection:

Class A:

- Randomized, controlled trial

Class B:

- Cohort study

Class C:

- Non-randomized trial with concurrent or historical controls
- Case-control study
- Study of sensitivity and specificity of a diagnostic test
- Population-based descriptive study

Class D:

- Cross-sectional study
- Case series
- Case report

B. Reports that Synthesize or Reflect upon Collections of Primary Reports

Class M:

- Meta-analysis
- Systematic review
- Decision analysis
- Cost-effectiveness analysis

Class R:

- Consensus statement
- Consensus report
- Narrative review

Class X:

- Medical opinion

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The guideline contains an annotated bibliography and discussion of the evidence supporting each recommendation. The type of supporting evidence is classified for selected recommendations (see "Major Recommendations").

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

- Guideline implementation may help the clinician make risk-benefit treatment decisions regarding anticoagulation therapy and appropriately manage patients on anticoagulation therapy to maximize safety and efficacy.
- There are no circumstances under which patients absolutely should or should not receive anticoagulation therapy. Clinicians must consider the risks and benefits of anticoagulation therapy for a patient based upon the individual's risk for thrombosis if not treated weighed against their risk of bleeding if treated.

POTENTIAL HARMS

- The major potential side effect of anticoagulation therapy is bleeding either from supratherapeutic effect or by accentuating the blood loss of patients with an existing source of bleeding.
- The major potential harm of withholding anticoagulation therapy is risk for thrombosis.
- Refer to the "Major Recommendations" field for additional details.
- Refer to Annotation Appendix C of the original guideline document for a list of drug and herb interactions and a description of the mechanism of interaction with warfarin.

CONTRAINDICATIONS

CONTRAINDICATIONS

There are no absolute contraindications to anticoagulant therapy. The decision to treat a patient with anticoagulant drugs takes into account an individual patient's risk for thrombosis if not treated weighed against the risk of bleeding while on anticoagulation therapy. Refer to Annotation 3 in the "Major Recommendations" section for relative contraindications to warfarin therapy and to Annotation 10 for relative contraindications to heparin and derivatives.

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

- These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients, and are not intended either to replace a clinician's judgment or to establish a protocol for all patients with a particular condition. A guideline will rarely establish the only approach to a problem.
- This clinical guideline should not be construed as medical advice or medical opinion related to any specific facts or circumstances. Patients are urged to consult a health care professional regarding their own situation and any specific medical questions they may have.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better
Living with Illness
Staying Healthy

IOM DOMAIN

Effectiveness
Patient-centeredness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Anticoagulant therapy supplement. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2003 Nov. 54 p. [107 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2001 Sep (revised 2003 Nov)

GUIDELINE DEVELOPER(S)

Institute for Clinical Systems Improvement - Private Nonprofit Organization

GUIDELINE DEVELOPER COMMENT

Organizations participating in the Institute for Clinical Systems Improvement (ICSI): Affiliated Community Medical Centers, Allina Medical Clinic, Altru Health System, Aspen Medical Group, Avera Health, CentraCare, Columbia Park Medical Group, Community-University Health Care Center, Dakota Clinic, ENT Specialty Care, Fairview Health Services, Family HealthServices Minnesota, Family Practice Medical Center, Gateway Family Health Clinic, Gillette Children's Specialty Healthcare, Grand Itasca Clinic and Hospital, HealthEast Care System, HealthPartners Central Minnesota Clinics, HealthPartners Medical Group and Clinics, Hutchinson Area Health Care, Hutchinson Medical Center, Lakeview Clinic, Mayo Clinic, Mercy Hospital and Health Care Center, MeritCare, Mille Lacs Health System, Minnesota Gastroenterology, Montevideo Clinic, North Clinic, North Memorial Care System, North Suburban Family Physicians, Northwest Family Physicians, Olmsted Medical Center, Park Nicollet Health Services, Pilot City Health Center, Quello Clinic, Ridgeview Medical Center, River Falls Medical Clinic, Saint Mary's/Duluth Clinic Health System, St. Paul Heart Clinic, Sioux Valley Hospitals and Health System, Southside Community Health Services, Stillwater Medical Group, SuperiorHealth Medical Group, University of Minnesota Physicians, Winona Clinic, Ltd., Winona Health

ICSI, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; telephone, (952) 814-7060; fax, (952) 858-9675; e-mail: icsi.info@icsi.org; Web site: www.icsi.org.

SOURCE(S) OF FUNDING

The following Minnesota health plans provide direct financial support: Blue Cross and Blue Shield of Minnesota, HealthPartners, Medica, Metropolitan Health Plan, PreferredOne, and UCare Minnesota. In-kind support is provided by the Institute for Clinical Systems Improvement's (ICSI) members.

GUIDELINE COMMITTEE

Cardiovascular Steering Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Work Group Members: Bruce Burnett, MD (Work Group Leader) (Park Nicollet Health Services) (Internal Medicine); Stephen Kopecky, MD (Mayo Clinic) (Cardiology); Rajiv Pruthi, MD (Mayo Clinic) (Hematology); John Butler, MD (HealthPartners Medical Group) (Internal Medicine); Mark Morrow, MD (Aspen Medical Group) (Internal Medicine); Steven Reichl, MD (CentraCare Health System) (Internal Medicine); John Davenport, MD (Park Nicollet Health Services) (Neurology); Timothy Miley, MD (Park Nicollet Health Services) (Pathology); Jill Strykowski, RPh, MS (Park Nicollet Health Services) (Pharmacy); Julie Blanchette, RN (CentraCare Health System) (Nursing); Lori Wurth, RN (HealthPartners Medical Group) (Nursing); Beth Green, MBA, RRT (Institute for Clinical Systems Improvement) (Implementation Advisor); Peter Lynch, MPH (Institute for Clinical Systems Improvement) (Evidence Analyst); Sherri Huber, MT (ASCP) (Institute for Clinical Systems Improvement) (Facilitator)

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

In the interest of full disclosure, the Institute for Clinical Systems Improvement (ICSI) has adopted a policy of revealing relationships work group members have with companies that sell products or services that are relevant to this guideline topic. The reader should not assume that these financial interests will have an adverse impact on the content of the guideline, but they are noted here to fully inform readers. Readers of the guideline may assume that only work group members listed below have potential conflicts of interest to disclose.

Jill M. Strykowski, RPh, MS, is a consultant to Aventis.

Bruce Burnett, MD, is a member of the speakers bureau for Aventis, BMS, and Astra Zeneca; a consultant for Aventis, Astra Zeneca, and Sauiflo-organor; receives grant support from Aventis and BMC; and receives research support from Astra Zeneca.

Steve Kopecky is a consultant for Glaxo Smith Kline and received research support from BMS.

ICSI's conflict of interest policy and procedures are available for review on ICSI's website at www.icsi.org.

GUIDELINE STATUS

This is the current release of the guideline.

This release updates a previously published guideline: Institute for Clinical Systems Improvement (ICSI). Anticoagulation therapy supplement. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2002 Oct. 54 p.

GUIDELINE AVAILABILITY

Electronic copies: Available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](#).

Print copies: Available from ICSI, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; telephone, (952) 814-7060; fax, (952) 858-9675; Web site: www.icsi.org; e-mail: icsi.info@icsi.org.

AVAILABILITY OF COMPANION DOCUMENTS

The following is available:

- Anticoagulation therapy supplement. In: ICSI pocket guidelines. April 2003 edition. Bloomington (MN): Institute for Clinical Systems Improvement, 2003 Mar. pp. 40-50.

Print copies: Available from ICSI, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; telephone, (952) 814-7060; fax, (952) 858-9675; Web site: www.icsi.org; e-mail: icsi.info@icsi.org.

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on August 26, 2002. The information was verified by the guideline developer on September 23, 2002. This summary was updated by ECRI on May 7, 2004.

COPYRIGHT STATEMENT

This NGC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Guideline) is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

The abstracted ICSI Guidelines contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Guidelines are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Guidelines are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside

of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Guidelines are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Guidelines.

© 1998-2004 National Guideline Clearinghouse

Date Modified: 11/15/2004

The logo for FIRSTGOV, with "FIRST" in blue and "GOV" in red, separated by a small red star.

